These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37737714)

  • 21. A systematic review of sex differences in treatment outcomes among people with opioid use disorder receiving buprenorphine maintenance versus other treatment conditions.
    Ling S; Mangaoil R; Cleverley K; Sproule B; Puts M
    Drug Alcohol Depend; 2019 Apr; 197():168-182. PubMed ID: 30831429
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Are North Carolina clinicians delivering opioid use disorder treatment to Medicaid beneficiaries?
    Grove LR; Rao N; Domino ME
    Addiction; 2022 Nov; 117(11):2855-2863. PubMed ID: 35194878
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Racial and Ethnic Inequities in Buprenorphine and Methadone Utilization Among Reproductive-Age Women with Opioid Use Disorder: an Analysis of Multi-state Medicaid Claims in the USA.
    Xu KY; Schiff DM; Jones HE; Martin CE; Kelly JC; Bierut LJ; Carter EB; Grucza RA
    J Gen Intern Med; 2023 Dec; 38(16):3499-3508. PubMed ID: 37436568
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Community-Based Medication-First program for opioid use disorder: a hybrid implementation study protocol of a rapid access to buprenorphine program in Washington State.
    Banta-Green CJ; Owens MD; Williams JR; Sears JM; Floyd AS; Williams-Gilbert W; Kingston S
    Addict Sci Clin Pract; 2022 Jul; 17(1):34. PubMed ID: 35799210
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of an injectable monthly extended-release buprenorphine program in a low-barrier specialty addiction medicine clinic.
    Heil J; Salzman M; Hunter K; Baston KE; Milburn C; Schmidt R; Haroz R; Ganetsky VS
    J Subst Use Addict Treat; 2024 Jan; 156():209183. PubMed ID: 37879433
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of Receipt of Opioid Use Disorder-Related Telehealth Services and Medications for Opioid Use Disorder With Fatal Drug Overdoses Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM; Shoff C; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Psychiatry; 2023 May; 80(5):508-514. PubMed ID: 36988913
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review.
    Malta M; Varatharajan T; Russell C; Pang M; Bonato S; Fischer B
    PLoS Med; 2019 Dec; 16(12):e1003002. PubMed ID: 31891578
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Buprenorphine misinformation and willingness to treat patients with opioid use disorder among primary care-aligned health care professionals.
    Franz B; Dhanani LY; Hall OT; Brook DL; Fenstemaker C; Simon JE; Miller WC
    Addict Sci Clin Pract; 2024 Jan; 19(1):7. PubMed ID: 38243307
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trauma treatment for veterans in buprenorphine maintenance treatment for opioid use disorder.
    Meshberg-Cohen S; Black AC; DeViva JC; Petrakis IL; Rosen MI
    Addict Behav; 2019 Feb; 89():29-34. PubMed ID: 30243036
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data.
    Zhang P; Tossone K; Ashmead R; Bickert T; Bailey E; Doogan NJ; Mack A; Schmidt S; Bonny AE
    J Subst Abuse Treat; 2022 May; 136():108686. PubMed ID: 34953637
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?
    Rhee TG; Rosenheck RA
    Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association Between Hospital Adoption of an Emergency Department Treatment Pathway for Opioid Use Disorder and Patient Initiation of Buprenorphine After Discharge.
    Solomon KT; O'Connor J; Gibbons JB; Kilaru AS; Feder KA; Xue L; Saloner B; Stuart EA; Cole ES; Hulsey E; Meisel Z; Patel E; Donohue JM
    JAMA Health Forum; 2023 Mar; 4(3):e230245. PubMed ID: 36961457
    [TBL] [Abstract][Full Text] [Related]  

  • 33. What is success in treatment for opioid use disorder? Perspectives of physicians and patients in primary care settings.
    Hooker SA; Sherman MD; Lonergan-Cullum M; Nissly T; Levy R
    J Subst Abuse Treat; 2022 Oct; 141():108804. PubMed ID: 35643586
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints.
    Gertner AK; Robertson AG; Jones H; Powell BJ; Silberman P; Domino ME
    Health Serv Res; 2020 Jun; 55(3):383-392. PubMed ID: 32166761
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Office-Based Buprenorphine Treatment: Identifying Factors That Promote Retention in Opioid-Dependent Patients.
    Noe SR; Keller T
    J Addict Nurs; 2020; 31(1):23-29. PubMed ID: 32132421
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of Racial and Ethnic Disparities in the Use of Medication to Treat Opioid Use Disorder Among Pregnant Women in Massachusetts.
    Schiff DM; Nielsen T; Hoeppner BB; Terplan M; Hansen H; Bernson D; Diop H; Bharel M; Krans EE; Selk S; Kelly JF; Wilens TE; Taveras EM
    JAMA Netw Open; 2020 May; 3(5):e205734. PubMed ID: 32453384
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short communication: Relationship between social determinants and opioid use disorder treatment outcomes by gender.
    Parlier-Ahmad AB; Radic M; Svikis DS; Martin CE
    Drug Alcohol Depend; 2022 Mar; 232():109337. PubMed ID: 35123364
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systematic review and meta-analysis of changes in quality of life following initiation of buprenorphine for opioid use disorder.
    Golan OK; Totaram R; Perry E; Fortson K; Rivera-Atilano R; Entress R; Golan M; Andraka-Christou B; Whitaker D; Pigott T
    Drug Alcohol Depend; 2022 Jun; 235():109445. PubMed ID: 35430522
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Medications for Opioid Use Disorder Study: Methods and Initial Outcomes From an 18-Month Study of Patients in Treatment for Opioid Use Disorder.
    Dever JA; Hertz MF; Dunlap LJ; Richardson JS; Wolicki SB; Biggers BB; Edlund MJ; Bohm MK; Turcios D; Jiang X; Zhou H; Evans ME; Guy GP
    Public Health Rep; 2024; 139(4):484-493. PubMed ID: 38268479
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of opioid use disorder in primary care.
    Buresh M; Stern R; Rastegar D
    BMJ; 2021 May; 373():n784. PubMed ID: 34011512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.